ReviewWorld journal of urology2010
Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.
Review in World journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- The role of 5-alpha reductase inhibitors in transurethral resection of the prostate: a meta-analysis of randomised controlled trials.BJU international · 2026Pooled it
- Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.World journal of urology · 2020Trial
- 5α-reductase type 1 modulates insulin sensitivity in men.The Journal of clinical endocrinology and metabolism · 2014Trial
- [Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].Urologie (Heidelberg, Germany) · 2026Review
- Article
- Article
- Ethanol Extract ofJournal of cancer prevention · 2022Article
- Administration ofResearch and reports in urology · 2022Article
- Article
- Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.Pharmaceutical biology · 2019Article
- Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.Current urology reports · 2019Review
- Aconiti Lateralis Radix Preparata, the Dried Root ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated KinaseFrontiers in pharmacology · 2018Article
- Article
- Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.Scientific reports · 2016Article
- Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.Therapeutic advances in urology · 2016Review
- Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats.Nephro-urology monthly · 2016Article
- [Pharmacological treatment of benign prostatic hyperplasia].Der Urologe. Ausg. A · 2016Article
- Article
- Benign prostatic hyperplasia: a new metabolic disease?Journal of endocrinological investigation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBenign prostatic hyperplasia (BPH) is a progressive disease that is commonly associated with bothersome lower urinary tract symptoms (LUTS) and might result in complications, such as acute urinary retention and BPH-related surgery. Therefore, the goals of therapy for BPH are not only to improve LUTS in terms of symptoms and urinary flow, but also to identify those patients at a risk of unfavorable disease progression and to optimize their management. This article reviews the current status of therapy with 5alpha-reductase inhibitors (5ARIs), namely fiasteride and dutasteride, for men with LUTS and BPH.
methodData from key randomized controlled trials (Oxford level 1b) on the use of 5ARIs are analyzed.
resultsThe efficacy of 5ARIs either as monotherapy or in combination with alpha(1)-adrenoceptor antagonists in the management of LUTS and the impact of monotherapy and combined therapy on BPH progression are discussed. Further promises, including the withdrawal of the alpha-blocker from the combined medical treatment and the potential clinical implications from the use of 5ARIs for prostate cancer chemoprevention in patients receiving 5ARIs for symptomatic BPH are highlighted.
conclusionsCurrent evidence shows that 5ARIs are effective in treating LUTS and preventing disease progression and represent a recommended option in treatment guidelines for men who have moderate to severe LUTS and enlarged prostates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.